Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued
Reference number: GID-TA10327
Following on from information provided to NICE by the company in March 2021, the appraisal of Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.